Cover Image
市場調查報告書

Lanthio Pharma B.V. - 產品平台分析

Lanthio Pharma B.V. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 293970
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Lanthio Pharma B.V. - 產品平台分析 Lanthio Pharma B.V. - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 22 Pages
簡介

Lanthio Pharma B.V.是研發治療重病用lantipeptide藥的生物製藥企業,提供治療纖維症、中風,多發性硬化症,心臟衰竭用新藥劑候補。該公司同時也活用胜肽重組的乳酸鏈球菌。

本報告提供Lanthio Pharma B.V.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lanthio Pharma B.V.的基本資料

Lanthio Pharma B.V.概要

  • 主要資訊
  • 企業資料

Lanthio Pharma B.V.:R&D概要

  • 主要的治療範圍

Lanthio Pharma B.V.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Lanthio Pharma B.V.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Lanthio Pharma B.V.:藥物簡介

  • LP2
  • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure
  • Peptide to Agonize Galanin Receptor 2 for IBD and CNS Disorders

Lanthio Pharma B.V.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Lanthio Pharma B.V.:暫停中的計劃

Lanthio Pharma B.V.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05773CDB

Summary

Global Markets Direct's, 'Lanthio Pharma B.V. - Product Pipeline Review - 2014', provides an overview of the Lanthio Pharma B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lanthio Pharma B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lanthio Pharma B.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lanthio Pharma B.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lanthio Pharma B.V.'s pipeline products

Reasons to buy

  • Evaluate Lanthio Pharma B.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lanthio Pharma B.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lanthio Pharma B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lanthio Pharma B.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lanthio Pharma B.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lanthio Pharma B.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lanthio Pharma B.V. Snapshot
    • Lanthio Pharma B.V. Overview
    • Key Information
    • Key Facts
  • Lanthio Pharma B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • Lanthio Pharma B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Lanthio Pharma B.V. - Pipeline Products Glance
    • Lanthio Pharma B.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lanthio Pharma B.V. - Drug Profiles
    • LP2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Agonize Galanin Receptor 2 for IBD and CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lanthio Pharma B.V. - Pipeline Analysis
    • Lanthio Pharma B.V. - Pipeline Products by Target
    • Lanthio Pharma B.V. - Pipeline Products by Molecule Type
    • Lanthio Pharma B.V. - Pipeline Products by Mechanism of Action
  • Lanthio Pharma B.V. - Dormant Projects
  • Lanthio Pharma B.V. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lanthio Pharma B.V., Key Information
  • Lanthio Pharma B.V., Key Facts
  • Lanthio Pharma B.V. - Pipeline by Indication, 2014
  • Lanthio Pharma B.V. - Pipeline by Stage of Development, 2014
  • Lanthio Pharma B.V. - Monotherapy Products in Pipeline, 2014
  • Lanthio Pharma B.V. - Out-Licensed Products in Pipeline, 2014
  • Lanthio Pharma B.V. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Lanthio Pharma B.V. - Preclinical, 2014
  • Lanthio Pharma B.V. - Discovery, 2014
  • Lanthio Pharma B.V. - Pipeline by Target, 2014
  • Lanthio Pharma B.V. - Pipeline by Molecule Type, 2014
  • Lanthio Pharma B.V. - Pipeline Products by Mechanism of Action, 2014
  • Lanthio Pharma B.V. - Dormant Developmental Projects,2014

List of Figures

  • Lanthio Pharma B.V. - Pipeline by Top 10 Indication, 2014
  • Lanthio Pharma B.V. - Pipeline by Stage of Development, 2014
  • Lanthio Pharma B.V. - Monotherapy Products in Pipeline, 2014
  • Lanthio Pharma B.V. - Pipeline by Top 10 Target, 2014
  • Lanthio Pharma B.V. - Pipeline by Top 10 Molecule Type, 2014
  • Lanthio Pharma B.V. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top